Ladan Parhamifar
Overview
Explore the profile of Ladan Parhamifar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munter R, Bak M, Thomsen M, Parhamifar L, Stensballe A, Simonsen J, et al.
Int J Pharm
. 2024 Apr;
657:124129.
PMID: 38621615
Cationic liposomes specifically target monocytes in blood, rendering them promising drug-delivery tools for cancer immunotherapy, vaccines, and therapies for monocytic leukaemia. The mechanism behind this monocyte targeting ability is, however,...
2.
Weller A, Hansen M, Marie R, Hundahl A, Hempel C, Kempen P, et al.
Front Bioeng Biotechnol
. 2022 Sep;
10:965200.
PMID: 36159696
Unsuccessful clinical translation of orally delivered biological drugs remains a challenge in pharmaceutical development and has been linked to insufficient mechanistic understanding of intestinal drug transport. Live cell imaging could...
3.
Munter R, Bak M, Christensen E, Kempen P, Larsen J, Kristensen K, et al.
Acta Biomater
. 2022 Mar;
144:96-108.
PMID: 35314364
Stimulation of monocytes with immunomodulating agents can harness the immune system to treat a long range of diseases, including cancers, infections and autoimmune diseases. To this end we aimed to...
4.
Munter R, Stavnsbjerg C, Christensen E, Thomsen M, Stensballe A, Hansen A, et al.
Small
. 2022 Feb;
18(14):e2106529.
PMID: 35187804
Coating nanoparticles with poly(ethylene glycol) (PEG) is widely used to achieve long-circulating properties after infusion. While PEG reduces binding of opsonins to the particle surface, immunogenic anti-PEG side-effects show that...
5.
Stavnsbjerg C, Christensen E, Munter R, Henriksen J, Fach M, Parhamifar L, et al.
J Control Release
. 2022 Jan;
342:337-344.
PMID: 34973307
Systemic administration of toll-like receptor (TLR) agonists have demonstrated impressive preclinical results as an anti-cancer therapy due to their potent innate immune-stimulatory properties. The clinical advancement has, however, been hindered...
6.
Larsen J, Taebnia N, Dolatshahi-Pirouz A, Eriksen A, Hjorringgaard C, Kristensen K, et al.
RSC Chem Biol
. 2021 Aug;
2(4):1115-1143.
PMID: 34458827
Oral delivery is a highly preferred method for drug administration due to high patient compliance. However, oral administration is intrinsically challenging for pharmacologically interesting drug classes, in particular pharmaceutical peptides,...
7.
Backlund C, Parhamifar L, Minter L, Tew G, Andresen T
Mol Pharm
. 2019 May;
16(6):2462-2469.
PMID: 31095395
Delivering peptides and proteins with intracellular function represents a promising avenue for therapeutics, but remains a challenge due to the selective permeability of the plasma membrane. The successful delivery of...
8.
Parhamifar L, Andersen H, Moghimi S
Methods Mol Biol
. 2019 Mar;
1943:291-299.
PMID: 30838623
Cellular toxicity and/or cell death entail complex mechanisms that require multifaceted characterization. A detailed mechanistic assessment of cytotoxicity is essential for design and construction of more effective polycations for nucleic...
9.
Jensen A, Severin G, Hansen A, Fliedner F, Eliasen R, Parhamifar L, et al.
J Control Release
. 2017 Nov;
269:100-109.
PMID: 29122662
Liposomes are nanoparticles used in drug delivery that distribute over several days in humans and larger animals. Radiolabeling with long-lived positron emission tomography (PET) radionuclides, such as manganese-52 (Mn, T½=5.6days),...
10.
Ostrem R, Parhamifar L, Pourhassan H, Clergeaud G, Nielsen O, Kjaer A, et al.
J Control Release
. 2017 Jul;
262:212-221.
PMID: 28754610
The clinical use of liposomal drug delivery vehicles is often hindered by insufficient drug release. Here we present the rational design of liposomes optimized for secretory phospholipase A (sPLA) triggered...